A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.
Wim PiersonMarianne TuefferdFlorence HerschkeLeen SlaetsMarjolein CrabbeDorien VerstappenSteffi De PelsmaekerIan StricklandEdward J GaneChristian SchwabeYingjie ZhangPeter MeertsJoris VandenbosschePieter Van RemoortereInge VerbruggeAn De CreusPublished in: Antiviral therapy (2023)
JNJ-4964 administration led to changes in transcriptional profiles and immune cell activation phenotype, particularly for NK cells and B cells. Together, these changes could represent a set of biomarkers for the characterization of the immune response in CHB patients receiving TLR7 agonists.